Nappi, Rossella E.
Lete, IƱaki
Lee, Lulu K.
Flores, Natalia M.
Micheletti, Marie-Christine
Tang, Boxiong
Funding for this research was provided by:
Teva Branded Pharmaceutical Products R&D, Inc.
Article History
Received: 23 June 2017
Accepted: 28 December 2017
First Online: 18 January 2018
Ethics approval and consent to participate
: Electronic consent was obtained from all participants in the NHWS. The survey was granted exemption by the Essex Institutional Review Board (Lebanon, NJ). Essex Institutional Review Board, Lebanon, NJ, USA reviewed and approved the US NHWS 2013 survey
: Not applicable.
: REN is a consultant and/or speaker for Bayer Pharma, Eli Lilly, Gedeon Richter, HRA Pharma, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Shionogi, Teva, and Zambon SpA; IL is a consultant and/or speaker for HRA Pharma, Merck Sharp & Dohme, Nordic, and Teva; LKL is a full-time employee of Kantar Health, which received funding to conduct this study; NMF was a full-time employee of Kantar Health at the time this study was conducted; MCM is a consultant for Teva Europe Medical Affairs; BT is an employee of Teva Pharmaceuticals.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.